Core Viewpoint - The company, Kangdelai (603987), is actively maintaining good cooperation with many excellent clients and partners while promoting projects in medical engineering and industry-academia-research collaboration [1] Group 1 - The company is engaging in active communication with investors through interactive platforms [1] - The company emphasizes its commitment to fostering partnerships and collaborations in various projects [1]

Core Viewpoint - The company, Kangdelai (603987), is actively evaluating its strategic goals and operational execution through a SWOT analysis, aiming for healthy and high-quality development while implementing targeted strategic guidance across its subsidiaries [1] Group 1: Strategic Planning - The company has conducted a SWOT analysis to assess its current strategic execution and identify areas for improvement [1] - A multi-dimensional approach focusing on transformation, innovation, enhancement, and strengthening has been adopted for the strategic planning [1] - The planning work is progressing in an orderly manner, indicating a structured approach to achieving its strategic objectives [1]

Group 1 - The company is effectively advancing its established strategic goals across various areas including market, research and development, and manufacturing [2]

Core Viewpoint - The company, Kangdelai (603987), is actively expanding its market presence through various sales models and channels, focusing on both domestic and international markets [1] Domestic Market - The company primarily utilizes an agency production model for its domestic market [1] International Market - For the international market, the company employs both entrusted export and self-operated export as its main sales models [1] - The company is committed to expanding its international market presence through multiple strategies [1]

证券代码：603987 证券简称：康德莱 公告编号：2025-030 上海康德莱企业发展集团股份有限公司 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 6 日（星期四）至 11 月 12 日（星期三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 kdl@kdlchina.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 上海康德莱企业发展集团股份有限公司（以下简称"公司"）已于 2025 年 10 月 28 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了 解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 11 月 13 日（星 期四）15:00-16:30 参加 2025 年上海辖区上市公司三季报集体业绩说明会，就 投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年第三季度的经 营 ...

Core Viewpoint - 康德莱 is a leading enterprise in the medical device sector in China, specializing in medical puncture needles and related products, with a strong full-industry chain advantage and superior product quality and technology [1] Group 1: Business Performance - In Q3 2025, 康德莱 reported revenue of 1.721 billion yuan, ranking 15th among 50 companies in the industry, while the industry leader, 英科医疗, achieved revenue of 7.425 billion yuan [2] - The net profit for the same period was 214 million yuan, also ranking 15th in the industry, with the top performer, 乐普医疗, reporting a net profit of 996 million yuan [2] Group 2: Financial Ratios - As of Q3 2025, 康德莱's debt-to-asset ratio was 28.00%, down from 29.49% year-on-year, which is higher than the industry average of 23.66% [3] - The gross profit margin for Q3 2025 was 32.59%, an increase from 31.30% year-on-year, but still below the industry average of 48.78% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 29.67% to 34,100, while the average number of circulating A-shares held per shareholder decreased by 22.88% to 12,800 [5] - New significant shareholders include 招商成长量化选股股票A and 医疗器械ETF, while 国寿安保智慧生活股票A and 招商量化精选股票发起式A exited the top ten circulating shareholders list [5] Group 4: Executive Compensation - The chairman, 张宪淼, maintained a salary of 1 million yuan for 2024, while the general manager, 张维鑫, saw a salary increase to 1.2278 million yuan, up by 347,800 yuan from 2023 [4]

Group 1 - The core point of the announcement is the decision made by the Supervisory Board of Shanghai Kangdai Enterprise Development Group Co., Ltd. regarding the third quarter report for 2025 and the proposal to abolish the Supervisory Board [1][2][4]. - The Supervisory Board meeting was held on October 27, 2025, with all three supervisors present, and the meeting complied with relevant laws and regulations [1][2]. - The third quarter report for 2025 was approved, confirming that the report's preparation and review processes met legal and regulatory requirements, and accurately reflected the company's operational results and financial status [2][3]. Group 2 - The proposal to abolish the "Rules of Procedure for Supervisory Meetings" was approved, indicating a significant structural change within the company as it plans to eliminate the Supervisory Board altogether [4][5]. - The proposal will be submitted for review at the company's second extraordinary general meeting of shareholders in 2025 [6]. - The second extraordinary general meeting of shareholders is scheduled for November 13, 2025, and will utilize both on-site and online voting methods [9][11].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603987 证券简称：康德莱 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一）主要会计数据和财务指标 单位：元 币种：人民币 ■ 注："本报告期"指本季度初至本季度末3个月期间，下同。 （二）非经常性损益项目和金额 □适用 √不适用 （三）主要会计数据、财务指标发生变动的情况、原因 □适用 √不适用 二、股东信息 （一）普通股股东总数和表决权恢复的优先股股东数量及前十名股东持股情况表 单位：股 ■ √适用 □不适用 单位：元 币种：人民币 ■ 对公司将《公开发行证券的公司信息披露解释性公告第1号一一非经常性损益》未列举的项目认定为非 ...

格隆汇10月27日丨康德莱(603987.SH)公布2025年第三季度报告，营业收入为5.96亿元，同比上升 2.44%；归属于上市公司股东的净利润为6850.48万元，同比上升14.33%；归属于上市公司股东的扣除非 经常性损益的净利润为6546.15万元，同比上升10.25%。 ...

Core Viewpoint - 康德莱 announced a board meeting to discuss amendments to the company's board meeting rules and reported its revenue structure for 2024, indicating a strong focus on the medical device manufacturing sector [1] Group 1: Company Announcements - 康德莱's fifth board meeting was held on October 27, 2025, in Shanghai, combining in-person and remote voting methods [1] - The meeting reviewed a proposal to amend certain provisions of the company's board meeting rules [1] Group 2: Financial Performance - For the year 2024, 康德莱's revenue composition is as follows: 99.6% from medical device manufacturing and 0.4% from other businesses [1] - As of the report, 康德莱's market capitalization stands at 4 billion yuan [1]